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Background:  Severe  respiratory  syncytial  virus  (RSV)  disease  occurs  predominantly  in children  under
6 months  of age.  There  is  no licensed  RSV  vaccine.  Protection  of young  infants  could  be  achieved  by
a  maternal  vaccine  to boost  titres  of  passively  transferred  protective  antibodies.  Data  on  the  level  and
kinetics  of functional  RSV-speciﬁc  antibody  at birth  and  over  the  early  infant  period  would  inform  vaccine
product  design.
Methods: From  a  birth  cohort  study  (2002–2007)  in  Kiliﬁ,  Kenya,  100  participants  were  randomly  selected
for  whom  cord  blood  and  2 subsequent  3-monthly  blood  samples  within  the  ﬁrst  year  of  life, were
available.  RSV antibodies  against  the A2  strain  of RSV  were  assayed  and  recorded  as  the  logarithm  (base
2)  plaque  reduction  neutralisation  test  (PRNT)  titre.  Analysis  by  linear  regression  accounted  for  within-
person  clustering.
Results:  The  geometric  mean  neutralisation  antibody  titre  was  10.6  (SD:  1.13)  at  birth  with  a  log-linear
decay  over  the  ﬁrst  6 months  of  life.  The  estimated  rate  of  decay  was  −0.58  (SD:  0.20)  log2PRNT  titre per
month  and a  half-life  of  36 days.  There  was  no signiﬁcant  interaction  between  cord  titre  and  rate  of  decay
with  age.  Mean  cord  titres  rose  and  fell  in a pattern  temporally  tracking  community  virus transmission.
Conclusions:  In this  study  population,  RSV  neutralising  antibody  titres  decay  approximately  two-fold
every  one  month.  The  rate  of decay  varies  widely  by  individual  but  is  not  related  to  titre  at  birth.  RSV
speciﬁc  cord  titres  vary  seasonally,  presumably  due  to maternal  boosting.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Background
Severe RSV disease occurs primarily in infancy and predomi-
antly among children 1–5 months of age [1]. Globally, RSV disease
ay  be responsible for nearly 200,000 deaths per year in young
hildren and 99% of these deaths occur in low income countries [2].
n annual rate of hospitalisation with RSV associated pneumonia
f 1–2 per 100 for children in the ﬁrst year of life has been reported
n a rural community in Coastal Kenya [1,3].
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Prevention of RSV disease is primarily targeted towards young
infants [4], for which two  vaccine strategies are appropriate: ﬁrst,
to vaccinate infants at the earliest age when able to develop a pro-
tective immune response with minimal reactogenicity, and second,
to boost the level of RSV-speciﬁc antibodies in pregnant women
before delivery to extend the duration of protective antibodies in
early infancy [5–7].
There is evidence which supports the idea that maternal speciﬁc
RSV antibodies provide protection from RSV disease [7,8]. Glezen
et al. demonstrated that infants born with higher levels of antibody
develop infection at a later age, and infants infected in the pres-
ence of moderate levels of serum antibody have milder illnesses
than infants infected with lower or undetectable levels of antibody
[7]. A case-control study in rural Mozambique showed that high
levels of antibodies of maternal origin were associated with pro-
tection against RSV disease [5]. A randomised double blind placebo
controlled trial among premature infants and infants with bron-
chopulmonary dysplasia showed that monthly prophylaxis with
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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alivizumab (a humanised monoclonal IgG antibody) was associ-
ted with a 55% reduction in hospitalisation as a result of RSV [9]. In
ddition, there are data that suggest a deﬁned level of neutralising
ntibody which protects against RSV disease [10].
The success of a maternal RSV vaccination strategy will be
overned by the degree to which a vaccine will boost levels of pro-
ective antibodies transferred by the mother to the infant and by
he rate at which those antibodies decay. In this study we provide
aseline data necessary to evaluate vaccine potential. Speciﬁcally,
n a birth cohort of infants from Kiliﬁ in Kenya, we  estimate the
ean of and variation in RSV neutralising (i.e. functional) antibody
n newborn cord blood, and its rate of decay in relation to starting
itre.
. Methods
.1. Study site and population
This study was conducted at the Kenya Medical Research Insti-
ute (KEMRI)—Wellcome Trust Collaborative Research Programme,
n Kiliﬁ, coastal Kenya [11]. Between 1999 and 2007, a birth cohort
tudy [12,13] was  conducted to investigate susceptibility to inva-
ive pneumococcal disease among children aged 0 to 23 months.
his study was a natural history study, with no intervention, in
hich cord and 3 monthly blood samples were collected for each
articipant.
The current study used archived serum samples of children who
ere participants of the Kiliﬁ Birth Cohort (KBC) study and who
ere residents of the Kiliﬁ Health and Demographic Surveillance
ystem (KHDSS). Characteristics of this study population have been
escribed before [11,12,14].
Approximately 6000 KBC study participants were recruited in
he maternity ward and at the maternal and child health clinic at
iliﬁ District Hospital (KDH). A random sample of 100 participants
rom the KBC study, recruited from the KDH maternity ward, were
elected from the study database regardless of RSV disease. Each
elected participant had at least 3 blood samples (speciﬁcally, a cord
lood and two follow up samples) each separated by approximately
 months.
The temporal pattern of cases of RSV associated severe pneumo-
ia was derived from continuous surveillance of children under 5
ears of age admitted to Kiliﬁ District Hospital, Kiliﬁ, which serves
he KHDSS population [1,15]. An RSV epidemic was  empirically
eﬁned to begin when at least 10% of tested samples were RSV pos-
tive or with the observation of at least 2 cases of RSV infection per
eek in each of 2 consecutive weeks and were deﬁned to continue
s long as these conditions were satisﬁed, with the requirement
hat an epidemic must last for ≥4 weeks as previously deﬁned [1].
hese data were used to compare with the temporal pattern of cord
itres.
The Kenya National Ethical Review Committee approved this
tudy.
.2. Laboratory procedures
Archived serum samples had been stored at −80 ◦C. The titre
f RSV neutralising antibodies was determined by a plaque
eduction neutralisation test (PRNT) as described previously [16].
he method incorporated a step in which serum samples were
ncubated at 56 ◦C in a water bath for 30 min  to inactivate com-
lement cascade proteins. The dilution of a test serum sample
equired to induce 50% neutralisation of a known titration of
SV A2 virus was determined using the Spearman Karber method
16]. (2015) 1797–1801
2.3. Statistical analyses
Data analysis was  conducted using STATA version 11.2 (College
Station, Texas). The laboratory data were merged with archived
data from the KBC and KHDSS databases for analysis. Sample PRNT
titres were logarithmically transformed (base 2) for all statistical
analyses. The titre of cord, ﬁrst and second samples for an individ-
ual were deﬁned as TC, T1 and T2, respectively. To offset bias on the
rate of decay arising from RSV infection, we applied the following
criteria. For individuals with T1 ≥ TC, all results for that individual
were excluded, and for individuals with T2 ≥ T1 the result for sam-
ple T2 was excluded. In addition, all samples collected at ages ≥7 m
after birth were excluded due to there being few in number and of
wide age range (7–11 m)  and a high likelihood that the measured
antibody would be active rather than passive. The rate of decay of
RSV speciﬁc log2PRNT titres from birth to <7 months of life was
determined by simple linear regression, accounting for clustering
of titres for samples from the same individual using the procedure
for Huber–White sandwich estimator. Possible interaction between
cord antibody titre and rate of decay of maternal antibodies was
tested using the model with individuals categorised by quartile of
titre at birth. Age dependence in the rate of decay of antibody titres
was evaluated by comparing model ﬁts using linear and quadratic
terms for age. The Wald test was used to evaluate the signiﬁcance
of removal of variables in nested models. To evaluate the effect of
infection on the antibody levels, the rate of decay of those partic-
ipants with at least 2 samples collected within an RSV epidemic
was estimated and compared to that of participants with at least
2 samples collected outside an RSV epidemic. A two  sample t-test
was used to compare the levels of neutralising antibodies and the
mean of the rates of decay between samples collected within and
outside an RSV epidemic and between binary covariates for birth-
weight (low birth weight <2.5 kg) measured using a weighing scale
at birth and gestation period (premature < 37 weeks) based on date
of last menstruation or by clinical evaluation.
3. Results
A total of 300 samples from 100 cohort participants were
selected. For 8 individuals, the second follow-up sample (T2) was
not available, therefore, 292 samples were screened for RSV spe-
ciﬁc neutralising antibodies. Applying the exclusion criteria as
described in the Methods, 18 additional samples were removed (9
samples with T2 ≥ T1 and 9 samples ≥7 months), leaving 274 sam-
ples from 100 participants (76 with 3 samples, 22 with 2 samples
and 2 with 1 sample) for analysis.
The frequency distribution of log-transformed PRNT titres for
cord blood samples was approximately normal (Fig. 1) with mean
concentration 10.6 (95% Conﬁdence Interval (CI) 10.3–10.7, vari-
ance 1.28) and median of 10.6 (Interquartile Range (IQR) 9.95–11.4,
10th percentile 8.87 log2PRNT). The mean birth weight in kilograms
of the participants in this study was 2.89 kg (SD: 0.49) and 19% were
born with low birthweight <2.5 kg (mean: 2.16; SD: 0.21). Only 63
participants had data on gestational period. The mean gestation
period in weeks was  38.6 (SD: 3.16). Of the 63 individuals with
gestational data, 15(24%) were born prematurely i.e. <37weeks
(mean 34.4; SD: 2.48). There was a signiﬁcant difference in the cord
blood neutralising antibody concentrations among the low birth
weight, 9.9 log2PRNT compared to the normal weight 10.7log2PRNT
(P = 0.02, t = −2.37) and between premature, 9.8 log2PRNT and not
premature, 10.9 log2PRNT (P = 0.002, t = −3.18).The distribution of log-transformed PRNT titres by age is shown
in Fig. 2, with the best ﬁt linear regression model (age range 0–<7 m)
giving an average reduction per month in log2PRNTof −0.58 (95%CI:
−0.65 and −0.51), and a predicted mean titre at birth of 10.5 (95%CI
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Fig. 1. Frequency distribution of maternally transferred RSV speciﬁc antibodies
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Table 1
The rate of decay, mean duration and Half-life for different categories of infants in
a  Kiliﬁ Birth Cohort.
Category Rate of decay
(log2PRNT/month)
Mean duration
in days
Half-life in
days
Overall −0.58 52 36
Within epidemic −0.56 54 37
Outside epidemic −0.67 45 31
<4months −0.64 47 32
>4months −0.51 59 41
Std dev.= 0.20
Percentile 25% 0.44, 75% 0.68
Mean=0.58
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Rate of decay (-log2 PRNT per month)
RSV cases admitted to Kiliﬁ District Hospital is shown in Fig. 4.
The results suggest that children born at the end and ﬁrst quar-log2 transformed PRNT titres) at birth for 100 infants born in Kiliﬁ, Kenya. The
verall mean (variance) and upper and lower quartile titres (log2PRNT) are shown.
0.2 and 10.7). The estimated rate of decay for participants for
hom all samples were collected within an RSV epidemic (n = 48;
amples = 98) was −0.56 log2PRNT per month (95%CI: −0.66 and
0.46) while those whose samples were all collected outside an
SV epidemic (n = 31; Samples = 66) was −0.67 log2PRNT per month
95%CI: −0.81 and −0.53). The difference in the rates of decay
etween those within an RSV epidemic and outside an epidemic
as not statistically signiﬁcant (P = 0.19, t = −1.32). The estimated
ate of decay for samples collected in children under 4 m of age was
0.64 log2PRNT per month (95%CI: −0.70 and −0.58). We explored
ossible age-dependence in the rate of decay of antibody titre by ﬁt-
ing a quadratic term for age in the regression model. The estimate
ad a signiﬁcant result (Wald test P = 0.001) and was  not consid-
red further, since the plots for the two models appeared similar
ith a predicted starting titre of 10.5 log2PRNT. The different rates
f decay with their corresponding half life and mean duration are
etailed in Table 1.
Results of regression analysis of the rate of decay of RSV anti-
odies by age and by quartile at birth (i.e. cord titre) is also shown
n Fig. 2. There was no evidence that slope varied by quartile, i.e. no
vidence of an interaction (Wald test comparing models with age
nd cord titre with or without interaction, P = 0.70.).
The distribution of individual rates of decay of RSV PRNT titres
shown in Fig. 3) is unimodal with mean −0.58 (i.e. half life of
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ig. 2. The decay in PRNT titre (log base 2 transformed) over the ﬁrst 6 months
f  life for a birth cohort, Kiliﬁ, Kenya, with best ﬁt linear decay model for all sam-
les (mean) and for each quartile cord level (q1–q4) assuming a ﬁxed rate of decay
−0.58 log2PRNT titre per month).Fig. 3. A histogram of the distribution of individual rates of decay showing the
overall mean (standard deviation; inter-quartile range), −log2PRNT/month.
36 days), variance 0.04, and IQR −0.44–0.68, i.e. 25% of the sample
had a half life of maternal antibodies of ≥48 ≤31 days.
Analysis of covariates on the rate of decay showed no statisti-
cally signiﬁcant effect on underweight <2.5 kg vs normal weight
>2.5 kg (log2PRNT per month −0.62 vs −0.57; P = 0.32) and pre-
mature birth vs full term (log2PRNT per month −0.66 vs −0.55;
P = 0.06).
Further analysis of the cord neutralisation titres by distribut-
ing them against date of collection and overlaying with weeklyter after an RSV epidemic have higher titres of RSV neutralising
Fig. 4. Dynamics of cord titres by time and transmission intensity. Grey symbols
denote individual cord titres by date of birth, black square markers the mean cord
titre by quarter (95% CI), and the vertical bars show the number of RSV IFAT positive
paediatric severe or very severe pneumonia admissions to Kiliﬁ District Hospital
2002–2008.
1 cine 33
a
i
(
4
u
w
a
a
o
t
a
m
d
N
c
a
s
s
a
l
i
s
m
t
t
T
t
c
i
t
p
o
d
t
w
i
l
(
o
a
3
v
p
O
w
o
r
t
t
m
i
a
d
l
i
i
t
c800 J.U. Nyiro et al. / Vac
ntibodies 10.8 log2PRNT (SD: 1.06) relative to children born mid
nter-epidemic and at the early stage of the epidemic10.0 log2PRNT
SD: 1.01) (P = 0.043, t = −2.09).
. Discussion
RSV is a major cause of severe respiratory disease among infants
nder 6 months of age [1]. Studies have found that infants born
ith high levels of RSV speciﬁc maternal antibodies are afforded
 degree of protection against the development of severe RSV
ssociated pneumonia during the ﬁrst months of life when the risk
f severe disease is greatest [8,17]. Hence, maternal vaccination
o boost protective speciﬁc antibodies in early infancy represents
 plausible disease prevention strategy for RSV. A number of
aternal vaccines based on the RSV F protein are now under-
evelopment [18] (http://www.clinicaltrials.gov/ct2/show/study/
CT01905215). This study was undertaken to deﬁne the baseline
haracteristics of maternal RSV neutralising antibody transfer
nd duration in support of the maternal vaccination intervention
trategy (http://sites.path.org/vaccinedevelopment/respiratory-
yncytial-virus-rsv/vaccine-development/).
In a low income predominantly rural population we  estimated
 mean concentration of cord neutralising antibody level of 10.6
og2PRNT. These results are slightly lower compared to those found
n a recent study conducted in Bangladesh [19]. However, other
tudies reported neutralising antibody titres lower than our esti-
ates [20,21]. We  also found that, the cord antibody level is related
o birthweight and gestational period; which are some of the fac-
ors reported to inﬂuence transplacental antibody transfer [22].
his indicates that infants born prior to 28 weeks are less likely
o gain antibody levels since RSV speciﬁc antibodies do not readily
ross the placenta before the 28th week of gestation.
We  identiﬁed the rate of decay to be −0.58 log2PRNT per month
n the ﬁrst 6 months of life, indicating a half life of 36 days. Since
he rate of decay might be affected by RSV transmission we  com-
ared rates for individuals whose samples were collected within
r outside of RSV epidemic periods and found a faster rate of
ecay (−0.67 log2PRNT per month; half-life 31 d) for the latter,
hough the difference was not statistically signiﬁcant. However,
e also noted that the rate of decay in those under 4 m of age
n the total sample (where maternal antibodies are highest and
east likely to be inﬂuenced by transmission) was  relatively high
−0.64 log2PRNT/month). Thus, we conclude that the rate of decay
f RSV speciﬁc maternal neutralising antibodies is between −0.58
nd −0.67 log2PRNT titres per month, i.e. with average half-life of
6–31 days.
The level of speciﬁc RSV neutralising antibody required to pre-
ent disease is not precisely known, but indirect estimates of a
rotective threshold are reported as 6 and 7.5 log2PRNT [10,20].
ur study suggests the vast majority of individuals to be born
ith titres above this threshold, and furthermore, that over 50%
f individuals remain so for around 5–6 m.  The indication is that
aising levels of cord RSV antibody by maternal vaccination above
he median level identiﬁed in this study would provide protec-
ion to most infants over the ﬁrst 5–6 m of life deemed to be the
ost critical for life-threatening RSV disease. Clearly, more work
s required to estimate directly the level of protective neutralising
ntibodies.
Our ﬁndings also indicate that the rate of decay of maternally
erived neutralising antibodies is independent of starting (cord)
evel. This result is of signiﬁcance since it suggests a constant
ncrease in beneﬁt from boosting titres, i.e. for each doubling rise
n antibody an increase in duration above a putative protective
hreshold of around 50 days. This means, a theoretical RSV vac-
ine which increases maternal antibody titres by approximately 4 (2015) 1797–1801
fold, would shift the age frequency curve of RSV disease to the right
by about 100 days. The above assertion assumes that cord RSV anti-
body boosted by a maternal vaccine would decay at the same rate
as cord antibody of the same level passively transferred from the
mother in the absence of vaccination.
Furthermore, although based on a small sample size, we ﬁnd
some evidence for an inverse relationship between population
level neutralising antibody titres (inferred from cord sera) and
population level virus transmission. RSV speciﬁc neutralising anti-
bodies decline in the absence of exposure and increase following
an increase in virus transmission at population level. As suggested
by Stensballe, this implies that a decline in herd immunity may
establish the conditions necessary for the spread of the virus [20].
Our study has a number of limitations. The results are appropri-
ate to a single rural developing country population. Future studies
would be of use to provide comparative data in sub-Saharan Africa,
in the Indian sub-continent, and in both urban and rural popu-
lations. The level and duration of maternal antibody may  also
vary according to concurrent maternal infections such as HIV and
malaria, which are all important factors which this study was not
designed to investigate. Measurement error in determining ges-
tational age and hence the pravelence of prematurity could be
addressed in future studies through use of standard ultrasound
procedures. RSV infects very early in life and the inﬂuence of trans-
mission on the estimated rate of decay is problematic. We  have
taken steps to remove the effect of RSV infection on estimating
the rates of decay and determined a realistic range within which
the real rate lies. However, there remains the possibility that early
infections in the presence of moderate to high titre maternal anti-
body might not have been detected. Analysis of cord level in relation
to prevalent RSV group within a population has not been under-
taken. Finally, neutralisation assays are frequently based on RSV A2
virus (without comparison with other strains or alternative group)
and not standardised between laboratories and this complicates
comparison of results between studies in different locations.
5. Conclusions
The results of this study provide precise estimates of the level
and duration of maternal RSV neutralisation antibody transfer for
a rural developing country population. Similar studies are required
in a range of settings. Interpretation of these results requires better
understanding of the relationship between the level of RSV-speciﬁc
neutralising antibody and protection from infection and disease,
and the capability of maternal vaccines to boost speciﬁc RSV pro-
tective antibodies in relation to existing antibody levels.
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